Abstract
Mepolizumab is indicated for eosinophilic asthma, nasal polyposis, eosinophilic granulomatosis and polyangiitis, and hypereosinophilic syndrome. There have been a number of case reports which suggest Mepolizumab may help in treatment of eosinophilic otitis media. However, patients with sensorineural hearing without clinical features of eosinophilic otitis media have not been shown to benefit from Mepolizumab treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
